AGH 3.85 0.00 Vol 0 AGL 17 0.00 Vol 0 BAS 1.7 0.00 Vol 0 BFM 16.4 0.00 Vol 0 BG23B 98.0011 0.00 Vol 0 BPH 7 0.00 Vol 0 DEVON 3.55 0.00 Vol 0 LOM 2.5 0.00 Vol 0 NTB 40 0.00 Vol 0 ONE 3.2 0.00 Vol 0 POLAR 5 0.00 Vol 0 SOM 15.25 0.00 Vol 0 WHHL 4.06 0.00 Vol 0 WWW 21.5 0.00 Vol 0
Market Closed:

Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Hamilton, Bermuda – 8 November 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced participation in investor conferences.  The full filing stated:

 

DUBLIN, November 7, 2018 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that thecompany will be webcasting its corporate presentations at four upcoming investor conferences.

 

·      Stifel Healthcare Conference in New York, NY on Wednesday, November 14, 2018 at9:30 a.m. EST / 2:30 p.m. GMT. Bruce Cozadd, chairman and chief executive officer,will provide an overview of the company and a business and financial update.

 

·      Jefferies London Healthcare Conference in London on Wednesday, November 14, 2018at 9:20 a.m. GMT / 4:20 a.m. EST. Iain McGill, senior vice president, JazzPharmaceuticals Europe and rest of world, will provide an overview of the company anda business and financial update.

 

·      Evercore ISI Healthcare Conference in Boston, MA on Tuesday, November 27, 2018 at8:00 a.m. EST / 1:00 p.m. GMT. Matt Young, executive vice president and chieffinancial officer, will provide an overview of the company and a business and financialupdate.

 

·      Piper Jaffray 30th Annual Healthcare Conference in New York, NY on Wednesday,November 28, 2018 at 11:00 a.m. EST / 4:00 p.m. GMT. Matt Young, executive vicepresident and chief financial officer, will provide an overview of the company and abusiness and financial update.

 

 

A live audio webcast of each presentation may be accessed from the Investors section of the JazzPharmaceuticals website at http://www.jazzpharmaceuticals.com. Please connect to the websiteprior to the start of the presentation to ensure adequate time for any software downloads that maybe necessary to listen to the webcast.

 

An archive of the webcast will be available for at least one week following the presentation on theInvestors section of the company’s website at http://www.jazzpharmaceuticals.com.

 

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focusedon improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and productcandidates with a focus in the areas of sleep and hematology/oncology. In these areas, JazzPharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginaseErwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine)liposome for injection in the U.S. and markets Erwinase®, Defitelio® (defibrotide) and Vyxeos® 44mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S. Forcountry-specific product information, please visit http://www.jazzpharmaceuticals.com/products.

For more information, please visit http://www.jazzpharmaceuticals.com/ and follow us on Twitter at

@JazzPharma.

Jazz Pharmaceuticals Contacts:

Investors:

Kathee Littrell

Vice President, Investor RelationsIreland, +353 1 634 7887

U.S., +1 650 496 2717

Media:

Jacqueline Kirby

Vice President, Corporate Affairs & Government RelationsIreland, +353 1 697 2141

U.S., +1 215 867 4910

TRADING HOURS

08:30-09:00 Price Discovery
09:00-16:30 Continuous Trading

CONTACT DETAILS

TEL: +1 (441) 292 7212
FAX: +1 (441) 292 7619
Email: info@bsx.com

LOCATION

30 Victoria Street
3rd Floor
Hamilton, Bermuda

MAILING ADDRESS

P.O. Box HM 1369
Hamilton HMFX

Disclaimer

 

The information contained in these pages has been obtained from sources which The Bermuda Stock Exchange believes are reliable. However, the accuracy of the information cannot and is not guaranteed and The Bermuda Stock Exchange makes no representation as to its accuracy or completeness. Neither this Web site, nor any information contained herein, constitutes advice or a solicitation to subscribe, purchase or sell any securities. The Bermuda Stock Exchange expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon any part of the contents of this site or any external sites referenced from this website.